Type de présentation | Oral presentation |
Titre | Ruthenium Brachytherapy in Uveal Melanoma |
But | Review of 136 uveal melanomas treated with ruthenium brachytherapy between 2019 and 2022. All tumors were treated with a top dosis of 100 Gy. |
Méthodes | Of 167 irradiations with ruthenium brachytherapy, 136 were applicated for uveal melanomas. We performed a retrospective analysis of the patients, the complications, local recurrence, and survival. In comparison with the literature available for ruthenium brachytherapy in uveal melanomas. On this moment three different radioactive plaques are available in UZLeuven for different tumor sizes and localisations. |
Résultats | Of 136 uveal melanomas, there were 3 patients with persistent vitreal hemorrahges, 1 patient with persistent diplopia the first 4 months, 8 with (amplification of their) serous detachments. One patient developed an orbital recurrence. Five patients died of melanoma during the follow-up. Three patients were re-treated because of local recurrence. |
Conclusion | Ruthenium brachytherapy is a good and safe procedure for treatment of uveal melanomas. |
Conflit d'intérêt | Non |
Nom | MISSOTTEN |
Initiales | G |
Institut | University Hospitals Leuven, Catholic University. |
Ville | Leuven |
Nom | Christiaens |
Initiales | M |
Institut | University Hospitals Leuven, Catholic University. |
Ville | Leuven |
Nom | Clement |
Initiales | P |
Institut | University Hospitals Leuven, Catholic University |
Ville | Leuven |
Nom | Van Ginderdeuren |
Initiales | R |
Institut | University Hospitals Leuven, Catholic University |
Ville | Leuven |
Nom | Van Calster |
Initiales | J |
Institut | University Hospitals Leuven, Leuven University |
Ville | Leuven |